Status:
COMPLETED
Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease
Lead Sponsor:
Catalysis SL
Conditions:
Breast Fibrocystic Disease
Eligibility:
FEMALE
20+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.
Eligibility Criteria
Inclusion
- Patients with clinical and ultrasonographic confirmation of breast fibrocystic disease.
- Patients older than 20 years.
- Female patients.
- Informed consent.
Exclusion
- Presents of another disease not well controlled.
- Pregnant women or lactating.
- Patient which are receiving another products from other investigations trials.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00967681
Start Date
September 1 2009
End Date
April 1 2011
Last Update
May 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Ramón González Coro" Gynecologic and Obstetric Hospital
Havana, La Habana, Cuba, 10400